How to buy ImmunoGen (IMGN) stock

ImmunoGen, Inc is a biotechnology business based in the US. ImmunoGen shares (IMGN) are listed on the NASDAQ and all prices are listed in US Dollars. ImmunoGen employs 79 staff and has a trailing 12-month revenue of around 0.00.

ImmunoGen stock price (NASDAQ: IMGN)

Use our graph to track the performance of IMGN stocks over time.

ImmunoGen shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$6.18
52-week range	$3.38 - $10.88
50-day moving average	$6.31
200-day moving average	$7.41
Wall St. target price	$9.93
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.19

Buy ImmunoGen shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy ImmunoGen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of ImmunoGen, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ImmunoGen price performance over time

Historical closes compared with the close of $6.18 from 2021-05-28

1 week (2021-07-14)	N/A
1 month (2021-06-25)	-11.21%
3 months (2021-04-21)	N/A
6 months (2021-01-21)	N/A

1 year (2020-07-21)	N/A
2 years (2019-07-21)	N/A
3 years (2018-07-21)	N/A
5 years (2016-07-21)	N/A

ImmunoGen financials

Revenue TTM	$134.7 million
Gross profit TTM	$17.7 million
Return on assets TTM	-5.2%
Return on equity TTM	-109.61%
Profit margin	-36.62%
Book value	$0.47
Market capitalisation	$1.1 billion

TTM: trailing 12 months

Shorting ImmunoGen shares

There are currently 22.1 million ImmunoGen shares held short by investors – that's known as ImmunoGen's "short interest". This figure is 4.1% down from 23.1 million last month.

There are a few different ways that this level of interest in shorting ImmunoGen shares can be evaluated.

ImmunoGen's "short interest ratio" (SIR)

ImmunoGen's "short interest ratio" (SIR) is the quantity of ImmunoGen shares currently shorted divided by the average quantity of ImmunoGen shares traded daily (recently around 2.0 million). ImmunoGen's SIR currently stands at 10.82. In other words for every 100,000 ImmunoGen shares traded daily on the market, roughly 10820 shares are currently held short.

However ImmunoGen's short interest can also be evaluated against the total number of ImmunoGen shares, or, against the total number of tradable ImmunoGen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ImmunoGen's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 ImmunoGen shares in existence, roughly 110 shares are currently held short) or 0.1225% of the tradable shares (for every 100,000 tradable ImmunoGen shares, roughly 123 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against ImmunoGen.

Find out more about how you can short ImmunoGen stock.

ImmunoGen share dividends

We're not expecting ImmunoGen to pay a dividend over the next 12 months.

ImmunoGen share price volatility

Over the last 12 months, ImmunoGen's shares have ranged in value from as little as $3.38 up to $10.88. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmunoGen's is 1.3036. This would suggest that ImmunoGen's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

ImmunoGen overview

ImmunoGen, Inc. , a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S.

Frequently asked questions

What percentage of ImmunoGen is owned by insiders or institutions?
Currently 0.507% of ImmunoGen shares are held by insiders and 92.87% by institutions. How many people work for ImmunoGen?
Latest data suggests 79 work at ImmunoGen. When does the fiscal year end for ImmunoGen?
ImmunoGen's fiscal year ends in December. Where is ImmunoGen based?
ImmunoGen's address is: 830 Winter Street, Waltham, MA, United States, 02451-1477 What is ImmunoGen's ISIN number?
ImmunoGen's international securities identification number is: US45253H1014 What is ImmunoGen's CUSIP number?
ImmunoGen's Committee on Uniform Securities Identification Procedures number is: 45253H101